Get the Stockscreener App
312.51
2.13%
-6.81
After Hours:
312.51
Beone Medicines Ltd Adr stock is traded at $312.51, with a volume of 196.79K.
It is down -2.13% in the last 24 hours and up +6.10% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
See More
Previous Close:
$319.32
Open:
$313.91
24h Volume:
196.79K
Relative Volume:
0.54
Market Cap:
$34.25B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-50.08
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
+8.47%
1M Performance:
+6.10%
6M Performance:
+32.03%
1Y Performance:
+0.00%
1-Day Range:
$311.77
$318.64
1-Week Range:
$295.68
$330.63
52-Week Range:
$172.67
$330.63
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 39,936 Shares - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 11,013 Shares of Stock - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells $15,164,809.28 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 1-Year High – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 12-Month HighWhat's Next? - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Lai Wang Sells 259 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
AFC Gamma (NASDAQ:AFCG) Shares Down 4.9% – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 1,363 Shares of Stock - MarketBeat
BeOne Medicines stock rating reiterated at Outperform by RBC Capital - Investing.com
BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beone Medicines Ltd Adr Stock (ONC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wu Xiaobin | President and COO |
Aug 14 '25 |
Option Exercise |
156.45 |
39,936 |
6,247,989 |
39,936 |
| Wu Xiaobin | President and COO |
Aug 13 '25 |
Sale |
304.16 |
49,858 |
15,164,818 |
0 |
| Wu Xiaobin | President and COO |
Aug 14 '25 |
Sale |
305.06 |
39,936 |
12,182,818 |
0 |
| Lee Chan Henry | SVP, General Counsel |
Aug 13 '25 |
Option Exercise |
177.90 |
8,230 |
1,464,080 |
8,230 |
| Lee Chan Henry | SVP, General Counsel |
Aug 13 '25 |
Sale |
300.45 |
11,013 |
3,308,877 |
0 |
0.67%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):